Dover Weakness Seen as Overdone and 4 Stock Analyses Attracting Attention

Gilead Sciences Inc. (NASDAQ:GILD): Current Price: $79.02

According to RBC Capital expectations, investors over the next 12-20 months may start giving Gilead credit for the development of a new HIV treatment that will be able to replace its current Viread treatment which is going generic in 2019. The firm believes that the stock may move towards or over $100 due to this factor, and it keeps its Outperform rating on the stock.